Literature DB >> 18382999

Preliminary results of fetal Rhc examination in plasma of pregnant women with anti-c.

A Orzińska1, K Guz, E Brojer, B Zupańska.   

Abstract

OBJECTIVES: Anti-Rhc antibodies may be the reason for the hemolytic disease of the newborn, therefore, noninvasive Rhc determination is important for pregnancy monitoring. For this purpose, we decided to introduce real-time polymerase chain reaction (PCR) method.
METHODS: Blood from 200 donors, plasma and whole-blood from 11 Rhc-negative mothers, as well as blood from fathers and newborns were examined. Rhc sensitivity and specificity were first determined by real-time PCR using genomic DNA from donors. The same Rhc genotyping method was used for fetal Rhc detection in maternal plasma. To confirm the fetal Rhc-negative result, plasma was tested with a panel of biallelic insertion/deletion polymorphisms for the presence of fetal DNA.
RESULTS: The c allele assay showed full specificity. The mean Ct value for one copy of c allele diluted in C-negative DNA was determined from extrapolating the correlation curve as 39.9. Full concordance was observed between the fetal Rhc genotypes from maternal plasma and the newborn phenotypes.
CONCLUSIONS: Preliminary results show that it is possible to examine fetal c allele of RHCE gene in the plasma of pregnant women with anti-c by means of a noninvasive method. The diagnostic accuracy of the procedure, however, has yet to be confirmed in a larger group. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18382999     DOI: 10.1002/pd.1977

Source DB:  PubMed          Journal:  Prenat Diagn        ISSN: 0197-3851            Impact factor:   3.050


  1 in total

1.  14 Years of Polish Experience in Non-Invasive Prenatal Blood Group Diagnosis.

Authors:  Agnieszka Orzińska; Katarzyna Guz; Marzena Dębska; Małgorzata Uhrynowska; Zbigniew Celewicz; Mirosław Wielgo; Ewa Brojer
Journal:  Transfus Med Hemother       Date:  2015-11-03       Impact factor: 3.747

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.